» Articles » PMID: 17440983

Prognostic Relevance of the MTOR Pathway in Renal Cell Carcinoma: Implications for Molecular Patient Selection for Targeted Therapy

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2007 Apr 19
PMID 17440983
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The mammalian target of rapamycin (mTOR) pathway is up-regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC).

Methods: Immunohistochemical analysis using antibodies against pAkt, PTEN, p27, and pS6 was performed on a tissue microarray constructed from paraffin-embedded specimens from 375 patients treated by nephrectomy for RCC. The expression was associated with pathological parameters and survival.

Results: The mTOR pathway was more significantly altered in clear-cell RCC, high-grade tumors, and tumors with poor prognostic features. PS6 and PTEN showed the strongest associations with pathological parameters. Survival tree analysis regarding expression of cytoplasmic pAkt, nuclear pAkt, PTEN, cytoplasmic p27, and pS6 identified staining percentages of 40%, 10%, 75%, 7%, and 70%, respectively, as ideal cutoff values for stratification, with corresponding P-values of .03, .001, .02, .005, and <.0001, respectively. Interestingly, high nuclear pAkt expression was associated with a favorable prognosis, whereas high cytoplasmic pAkt expression was associated with a poor prognosis. In multivariate Cox regression analysis, ECOG PS, T classification, N classification, M classification, cytoplasmic Akt, nuclear pAkt, PTEN, and pS6 were independent prognostic factors of DSS.

Conclusions: Components of the mTOR pathway are significantly associated with pathological features and survival. Not all RCC tumor types seem to be equally amenable to mTOR targeted therapy. PTEN, pAkt, p27, and pS6 may serve as surrogate parameters for patient selection and predicting prognosis. Patients with a highly activated mTOR pathway should benefit most from this therapy. External validation of our results is recommended.

Citing Articles

BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma.

Liao C, Hu L, Jia L, Zhou J, Wang T, Kim K Nat Commun. 2025; 16(1):1543.

PMID: 39934163 PMC: 11814379. DOI: 10.1038/s41467-025-56955-y.


The HOX Gene Family's Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors.

Kopec K, Quaranto D, DeSouza N, Jarboe T, Islam H, Moscatello A Cancers (Basel). 2025; 17(2).

PMID: 39858044 PMC: 11763641. DOI: 10.3390/cancers17020262.


pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation.

Wang L, Cai F, Li Y, Lin X, Wang Y, Liang W Int J Nanomedicine. 2024; 19:9821-9841.

PMID: 39345910 PMC: 11430863. DOI: 10.2147/IJN.S469913.


Unconventional mechanism of action and resistance to rapalogs in renal cancer.

Yang J, Butti R, Cohn S, Toffessi-Tcheuyap V, Mal A, Nguyen M Proc Natl Acad Sci U S A. 2024; 121(25):e2310793121.

PMID: 38861592 PMC: 11194491. DOI: 10.1073/pnas.2310793121.


Low-Level Expression of p-S6 Is Associated with Nodal Metastasis in Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.

Gomez-de Castro C, Santos-Juanes R, Nunez-Gomez B, Fernandez-Vega I, Vivanco B, Fernandez-Velasco A Int J Mol Sci. 2024; 25(8).

PMID: 38673889 PMC: 11049968. DOI: 10.3390/ijms25084304.